Innate Pharma S.A.

Innate Pharma reported cash of EUR 25.4 million as of March 31, 2026. The call did not provide revenue, EPS, or gross margin figures. Management said lacutamab had FDA clearance for TELLOMAT-3 and expects Phase III initiation in the second half of 2026, subject to financing; PACIFIC-9 monalizumab data are expected in 2H 2026; and IPH4502 first-in-human data are expected at a medical conference before year-end. For IPH5201, interim MATIS data from 40 patients showed a 35.7% pCR rate in PD-L1 above 1% and 50% pCR in PD-L1 at least 50%, with no new or unexpected safety signals.

Jonathan Dickinson emphasized a focused strategy around three priority assets and said the company is making strong progress against that plan. He highlighted lacutamab as a meaningful CTCL opportunity, IPH4502 as a potentially differentiated Nectin-4 ADC with signals in post-EV urothelial cancer, and monalizumab as a partnered value driver with important future milestone, royalty and profit-sharing potential. His tone was constructive but disciplined, repeatedly tying execution to financing and upcoming clinical catalysts.

The CFO commentary was limited on the call, but management did provide the key balance-sheet figure: EUR 25.4 million in cash at March 31, 2026. On partnered programs, the company reiterated that monalizumab carries up to $1.275 billion of milestones, with $450 million already received and $825 million remaining eligible, while IPH5201 is worth up to $85 million in milestones with $60 million already received. Management also said AstraZeneca contribution requirements on PACIFIC-9 are now minimal because the agreement is close to its cap, and noted the company is pursuing non-dilutive financing for lacutamab.

Analysts focused on three main issues: the strength of the MATIS/IPH5201 signal versus broader benchmarks, the go-forward dose and potential indications for IPH4502, and whether a lacutamab partnership could close before Q3. Management said the IPH5201 data look promising versus a durvalumab backbone because pCR improved without added toxicity, but they want more patients before deciding on Phase III. On IPH4502, they said more detail on dose levels and go-forward indications will come at a medical conference later this year. On lacutamab, management said discussions are advanced and they are confident they can execute either a BD partnership or royalty financing in the relatively short term, but did not commit to a specific closing date.